[Androgens and Parkinson's disease: the role in humans and in experiment]

Parkinson's disease (PD) is the second most common neurodegenerative disease after Alzheimer's disease. There is evidence that PD has a wider prevalence among men, which indicates the existing role of sex hormones in the pathogenesis of the disease. The article presents an overview of studies devoted to the study of sex differences in the incidence and symptoms of PD. Drug therapy with androgens, androgen precursors, antiandrogens and drugs that modify androgen metabolism is available for the treatment of various endocrine conditions, having translational significance for PD, but none of these drugs has yet shown sufficient effectiveness. Although PD has now been proven to be more common in men than in women, androgens do not always have any effect on the symptoms or progression of the disease. 5α-reductase inhibitors have shown neuroprotective and anti-dyskinetic activity and need further investigation. Despite the fact that the neuroprotective effect of dutasteride was observed only before damage to DA neurons, the absence of a negative effect makes it an attractive drug for use in patients with PD due to its anti-dyskinetic properties.

 

Comments：

Studies have shown that Parkinson's disease is more prevalent in men, indicating a role of sex hormones in its pathogenesis, and while androgens and drugs that modify androgen metabolism have potential as treatment options, their effectiveness is yet to be fully proven; 5α-reductase inhibitors show promise for their neuroprotective and anti-dyskinetic properties, with dutasteride having attractive properties for use in PD patients due to its anti-dyskinetic effects, but further investigation is needed.

Related Products

Cat.No.	Product Name	Information
S1202	Dutasteride	Dutasteride (GI198745, GG-745) is a dual 5-α reductase inhibitor that inhibits conversion of testosterone to dihydrotestosterone (DHT).

Related Targets

5-alpha Reductase